S. Hedgecock

2.4k total citations · 1 hit paper
15 papers, 1.8k citations indexed

About

S. Hedgecock is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, S. Hedgecock has authored 15 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology and Allergy. Recurrent topics in S. Hedgecock's work include Asthma and respiratory diseases (14 papers), Respiratory and Cough-Related Research (9 papers) and Allergic Rhinitis and Sensitization (9 papers). S. Hedgecock is often cited by papers focused on Asthma and respiratory diseases (14 papers), Respiratory and Cough-Related Research (9 papers) and Allergic Rhinitis and Sensitization (9 papers). S. Hedgecock collaborates with scholars based in United Kingdom, United States and Switzerland. S. Hedgecock's co-authors include Martin Blogg, Jean Bousquet, K. Surrey, Marc Humbert, Helen Fox, Jon G. Ayres, Jean‐Louis Hébert, H. Fox, Richard Beasley and Giorgio Walter Canonica and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and British Journal of Dermatology.

In The Last Decade

S. Hedgecock

14 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

2004 839 citations Marc Humbert, Richard Beasley et al. Allergy profile →

Peers

S. Hedgecock

PHYSI

PRM

DERMA

IMMUN

Angel FowlerTaylor United States

J. Thirlwell United Kingdom

Sandhia Ponnarambil United States

Lynn E. Katz United States

Gun Almqvist Sweden

Paul J. Rowe United States

Albert F. Finn United States

Ashish Bansal United States

Mariana Fernandes United Kingdom

Brian D. Modena United States

Angel FowlerTaylor United States

S. Hedgecock

2.2k ×1.4

PHYSI

1.4k ×1.3

PRM

1.2k ×1.1

127 ×0.5

DERMA

396 ×2.0

IMMUN

Citations per year, relative to S. Hedgecock S. Hedgecock (= 1×) peers Angel FowlerTaylor

Countries citing papers authored by S. Hedgecock

Since Specialization

Citations

This map shows the geographic impact of S. Hedgecock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Hedgecock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Hedgecock more than expected).

Fields of papers citing papers by S. Hedgecock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Hedgecock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Hedgecock. The network helps show where S. Hedgecock may publish in the future.

Co-authorship network of co-authors of S. Hedgecock

This figure shows the co-authorship network connecting the top 25 collaborators of S. Hedgecock. A scholar is included among the top collaborators of S. Hedgecock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Hedgecock. S. Hedgecock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bousquet, Jean, Ulrich Wahn, Eli O. Meltzer, et al.. (2008). Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. European Respiratory Review. 17(107). 1–9. 6 indexed citations

Massanari, Marc, Farid Kianifard, Robert Maykut, et al.. (2006). Omalizumab Reduced Need for Steroid Bursts and Improved Treatment Effectiveness in Asthmatics on Inhaled Salmeterol and Fluticasone Combination Therapy. Journal of Allergy and Clinical Immunology. 117(2). S10–S10. 2 indexed citations

Berger, William, Nancy K. Ostrom, M. Solèr, et al.. (2005). Omalizumab significantly reduces asthma exacerbations in patients with severe persistent asthma: A pooled analysis. Journal of Allergy and Clinical Immunology. 115(2). S75–S75. 2 indexed citations

Meltzer, Eli O., et al.. (2005). Omalizumab, an anti-IgE antibody, significantly reduces emergency visits in patients with severe persistent asthma: A pooled analysis. Journal of Allergy and Clinical Immunology. 115(2). S76–S76. 1 indexed citations

Chipps, Bradley E., Jonathan Corren, Adam Finn, et al.. (2005). Omalizumab significantly improves quality of life in patients with severe persistent asthma. Journal of Allergy and Clinical Immunology. 115(2). S5–S5. 7 indexed citations

Slavin, Raymond G., et al.. (2005). Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE. Journal of Allergy and Clinical Immunology. 115(2). S76–S76. 2 indexed citations

Humbert, Marc, Richard Beasley, Jon G. Ayres, et al.. (2004). Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 60(3). 309–316. 839 indexed citations breakdown →

Vignola, A M, Marc Humbert, Jean Bousquet, et al.. (2004). Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 59(7). 709–717. 309 indexed citations

Bousquet, Jean, Pedro Cabrera, Neville Berkman, et al.. (2004). The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 60(3). 302–308. 312 indexed citations

10.

Corren, Jonathan, et al.. (2004). Omalizumab is effective in reducing asthma exacerbations irrespective of concomitant long-acting beta2-agonist use. Journal of Allergy and Clinical Immunology. 113(2). S36–S36. 1 indexed citations

11.

Dahl, Ronald, Jon G. Ayres, S. Hedgecock, et al.. (2004). Efficacy of omalizumab, an anti-IgE antibody, in patients with concomitant moderate-severe allergic asthma and persistent allergic rhinitis. Journal of Allergy and Clinical Immunology. 113(2). S37–S37. 2 indexed citations

12.

Harnest, Ulf, LP Boulet, S. Hedgecock, et al.. (2004). Omalizumab, an anti-IgE antibody, improves both asthma- and rhinitis-related quality of life in patients with concomitant moderate-severe disease. Journal of Allergy and Clinical Immunology. 113(2). S176–S176. 3 indexed citations

13.

Chervinsky, Paul, Thomas B. Casale, Robert G. Townley, et al.. (2003). Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Annals of Allergy Asthma & Immunology. 91(2). 160–167. 153 indexed citations

14.

Boulet, Louis‐Philippe, Giorgio Walter Canonica, Ronald Dahl, et al.. (2003). Omalizumab, an Anti-IgE Antibody, Provides Parallel Improvements in Symptoms of Allergic Asthma and Perennial Allergic Rhinitis in Patients With Both Diseases: The SOLAR Stud. CHEST Journal. 124(4). 105S–105S. 4 indexed citations

15.

Luger, Thomas A., E.J.M. van Leent, Michael Graeber, et al.. (2001). SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. British Journal of Dermatology. 144(4). 788–794. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact